BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3296210)

  • 1. The alpha interferons: clinical overview.
    Spiegel RJ
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):1-12. PubMed ID: 3296210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intron A (interferon alfa-2b): clinical overview and future directions.
    Spiegel RJ
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):89-101. PubMed ID: 3532338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha interferons: a clinical overview.
    Spiegel RJ
    Urology; 1989 Oct; 34(4 Suppl):75-9; discussion 87-96. PubMed ID: 2678686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon in the treatment of nodular lymphomas.
    Urba WJ; Longo DL
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):40-7. PubMed ID: 3541218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-alpha in the treatment of hematologic neoplasms].
    Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG; Smith JW; Urba WJ; Clark JW; Itri LM; Evans LM; Schoenberger C; Longo DL
    N Engl J Med; 1988 Jun; 318(22):1409-13. PubMed ID: 3367950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfa interferon: combinations with other antineoplastic modalities.
    Bonnem EM
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):48-60. PubMed ID: 3296212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
    Foon KA; Bunn PA
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotherapy with interferon--1988.
    Figlin RA
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon therapy in hematologic neoplasms].
    Schwarzinger I; Bettelheim P; Lechner K
    Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Various aspects and results of therapy with interferon].
    Niederle N
    Arzneimittelforschung; 1988 Mar; 38(3A):449-53. PubMed ID: 2456071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
    Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
    Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
    Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant alpha interferons 1986: a review.
    Lindquist DL; Burns CP
    Iowa Med; 1987 Jan; 77(1):32, 34, 36. PubMed ID: 3818250
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic response modifiers: the interferon alfa experience.
    Koeller JM
    Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S11-5. PubMed ID: 2481396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha interferons in hairy cell leukaemia: a clinical model of biological therapy for cancer.
    Quesada JR
    Interferon; 1987; 8():111-34. PubMed ID: 3316039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.